Entering text into the input field will update the search result below

Royalty Pharma sells 20% of its royalty interest in Ibrutinib

Aug. 12, 2013 11:11 AM ETQuest Diagnostics Incorporated (DGX) StockJNJ, PCYC, DGXBy: David Yelle, SA News Editor2 Comments
  • Royalty Pharma says that pursuant to its collaboration with Aisling Capital and Clarus Ventures, it has sold the two companies around 20% of its royalty interest in Ibrutinib it recently acquired from Quest Diagnostics (DGX -0.2%).
  • In payment, its will receive a pro rata percentage of the $485M it paid to Quest for the royalty.
  • Pharmacyclics (PCYC +0.1%) and Johnson & Johnson (JNJ +0.3%) subsidiary Janssen Pharmaceuticals filed Ibrutinib with the FDA in July 2013 for the treatment of lymphoma and relapsed/refractory chronic lymphocytic leukemia, and currently has received three of the eight Breakthrough Therapy Designations granted by the FDA to date in oncology.

Recommended For You

About DGX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
DGX--
Quest Diagnostics Incorporated
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.